The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Peptide Based Gastrointestinal Disorders Therapeutics-Global Market Insights and Sales Trends 2024
Synopsis
Gastrointestinal disorders refer to diseases involving the gastrointestinal tract, namely the esophagus, stomach, small intestine, large intestine and rectum, and the accessory organs of digestion, the liver, gallbladder, and pancreas.
The global Peptide Based Gastrointestinal Disorders Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Peptide Based Gastrointestinal Disorders Therapeutics in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, are propelling Peptide Based Gastrointestinal Disorders Therapeutics market. Teduglutide, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Linaclotide segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Peptide Based Gastrointestinal Disorders Therapeutics market, driven by demand from China, the second largest economy with some signs of stabilising, the Peptide Based Gastrointestinal Disorders Therapeutics market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Peptide Based Gastrointestinal Disorders Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Peptide Based Gastrointestinal Disorders Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Peptide Based Gastrointestinal Disorders Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Peptide Based Gastrointestinal Disorders Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Peptide Based Gastrointestinal Disorders Therapeutics covered in this report include Takeda, Ironwood Pharmaceuticals, Astellas Pharma, Allergan and Takeda Pharmaceutical, etc.
The global Peptide Based Gastrointestinal Disorders Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Takeda
Ironwood Pharmaceuticals
Astellas Pharma
Allergan
Takeda Pharmaceutical
Global Peptide Based Gastrointestinal Disorders Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Peptide Based Gastrointestinal Disorders Therapeutics market, Segment by Type:
Teduglutide
Linaclotide
Others
Global Peptide Based Gastrointestinal Disorders Therapeutics market, by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Peptide Based Gastrointestinal Disorders Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Gastrointestinal disorders refer to diseases involving the gastrointestinal tract, namely the esophagus, stomach, small intestine, large intestine and rectum, and the accessory organs of digestion, the liver, gallbladder, and pancreas.
The global Peptide Based Gastrointestinal Disorders Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Peptide Based Gastrointestinal Disorders Therapeutics in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, are propelling Peptide Based Gastrointestinal Disorders Therapeutics market. Teduglutide, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Linaclotide segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Peptide Based Gastrointestinal Disorders Therapeutics market, driven by demand from China, the second largest economy with some signs of stabilising, the Peptide Based Gastrointestinal Disorders Therapeutics market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Peptide Based Gastrointestinal Disorders Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Peptide Based Gastrointestinal Disorders Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Peptide Based Gastrointestinal Disorders Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Peptide Based Gastrointestinal Disorders Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Peptide Based Gastrointestinal Disorders Therapeutics covered in this report include Takeda, Ironwood Pharmaceuticals, Astellas Pharma, Allergan and Takeda Pharmaceutical, etc.
The global Peptide Based Gastrointestinal Disorders Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Takeda
Ironwood Pharmaceuticals
Astellas Pharma
Allergan
Takeda Pharmaceutical
Global Peptide Based Gastrointestinal Disorders Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Peptide Based Gastrointestinal Disorders Therapeutics market, Segment by Type:
Teduglutide
Linaclotide
Others
Global Peptide Based Gastrointestinal Disorders Therapeutics market, by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Peptide Based Gastrointestinal Disorders Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Peptide Based Gastrointestinal Disorders Therapeutics
1.1 Peptide Based Gastrointestinal Disorders Therapeutics Market Overview
1.1.1 Peptide Based Gastrointestinal Disorders Therapeutics Product Scope
1.1.2 Peptide Based Gastrointestinal Disorders Therapeutics Market Status and Outlook
1.2 Global Peptide Based Gastrointestinal Disorders Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Region (2018-2029)
1.4 Global Peptide Based Gastrointestinal Disorders Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Peptide Based Gastrointestinal Disorders Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Peptide Based Gastrointestinal Disorders Therapeutics Market Size (2018-2029)
1.6.1 North America Peptide Based Gastrointestinal Disorders Therapeutics Market Size (2018-2029)
1.6.2 Europe Peptide Based Gastrointestinal Disorders Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Peptide Based Gastrointestinal Disorders Therapeutics Market Size (2018-2029)
1.6.4 Latin America Peptide Based Gastrointestinal Disorders Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Peptide Based Gastrointestinal Disorders Therapeutics Market Size (2018-2029)
2 Peptide Based Gastrointestinal Disorders Therapeutics Market by Type
2.1 Introduction
2.1.1 Teduglutide
2.1.2 Linaclotide
2.1.3 Others
2.2 Global Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Peptide Based Gastrointestinal Disorders Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Peptide Based Gastrointestinal Disorders Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Peptide Based Gastrointestinal Disorders Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Peptide Based Gastrointestinal Disorders Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Peptide Based Gastrointestinal Disorders Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Peptide Based Gastrointestinal Disorders Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Peptide Based Gastrointestinal Disorders Therapeutics Revenue Breakdown by Type (2018-2029)
3 Peptide Based Gastrointestinal Disorders Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Hospital Pharmacies
3.1.2 Retail Pharmacies
3.1.3 Online Pharmacies
3.2 Global Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Peptide Based Gastrointestinal Disorders Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Peptide Based Gastrointestinal Disorders Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Peptide Based Gastrointestinal Disorders Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Peptide Based Gastrointestinal Disorders Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Peptide Based Gastrointestinal Disorders Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Peptide Based Gastrointestinal Disorders Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Peptide Based Gastrointestinal Disorders Therapeutics Revenue Breakdown by Application (2018-2029)
4 Peptide Based Gastrointestinal Disorders Therapeutics Competition Analysis by Players
4.1 Global Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Peptide Based Gastrointestinal Disorders Therapeutics as of 2022)
4.3 Date of Key Players Enter into Peptide Based Gastrointestinal Disorders Therapeutics Market
4.4 Global Top Players Peptide Based Gastrointestinal Disorders Therapeutics Headquarters and Area Served
4.5 Key Players Peptide Based Gastrointestinal Disorders Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Peptide Based Gastrointestinal Disorders Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Takeda
5.1.1 Takeda Profile
5.1.2 Takeda Main Business
5.1.3 Takeda Peptide Based Gastrointestinal Disorders Therapeutics Products, Services and Solutions
5.1.4 Takeda Peptide Based Gastrointestinal Disorders Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Takeda Recent Developments
5.2 Ironwood Pharmaceuticals
5.2.1 Ironwood Pharmaceuticals Profile
5.2.2 Ironwood Pharmaceuticals Main Business
5.2.3 Ironwood Pharmaceuticals Peptide Based Gastrointestinal Disorders Therapeutics Products, Services and Solutions
5.2.4 Ironwood Pharmaceuticals Peptide Based Gastrointestinal Disorders Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Ironwood Pharmaceuticals Recent Developments
5.3 Astellas Pharma
5.3.1 Astellas Pharma Profile
5.3.2 Astellas Pharma Main Business
5.3.3 Astellas Pharma Peptide Based Gastrointestinal Disorders Therapeutics Products, Services and Solutions
5.3.4 Astellas Pharma Peptide Based Gastrointestinal Disorders Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Allergan Recent Developments
5.4 Allergan
5.4.1 Allergan Profile
5.4.2 Allergan Main Business
5.4.3 Allergan Peptide Based Gastrointestinal Disorders Therapeutics Products, Services and Solutions
5.4.4 Allergan Peptide Based Gastrointestinal Disorders Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Allergan Recent Developments
5.5 Takeda Pharmaceutical
5.5.1 Takeda Pharmaceutical Profile
5.5.2 Takeda Pharmaceutical Main Business
5.5.3 Takeda Pharmaceutical Peptide Based Gastrointestinal Disorders Therapeutics Products, Services and Solutions
5.5.4 Takeda Pharmaceutical Peptide Based Gastrointestinal Disorders Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Takeda Pharmaceutical Recent Developments
6 North America
6.1 North America Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Peptide Based Gastrointestinal Disorders Therapeutics Market Dynamics
11.1 Peptide Based Gastrointestinal Disorders Therapeutics Industry Trends
11.2 Peptide Based Gastrointestinal Disorders Therapeutics Market Drivers
11.3 Peptide Based Gastrointestinal Disorders Therapeutics Market Challenges
11.4 Peptide Based Gastrointestinal Disorders Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
